KURA ONCOLOGY INC. -

Kura Oncology to Report Third Quarter 2022 Financial Results  

27 окт 2022 06:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

26 окт 2022 06:30:01 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

01 сен 2022 06:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Second Quarter 2022 Financial Results

03 авг 2022 15:03:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

02 авг 2022 06:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Report Second Quarter 2022 Financial Results

27 июл 2022 06:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

26 май 2022 06:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Reports First Quarter 2022 Financial Results

04 май 2022 15:05:01 Источник Nasdaq GlobeNewswire

Kura Oncology to Report First Quarter 2022 Financial Results

27 апр 2022 06:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

08 апр 2022 12:00:00 Источник Nasdaq GlobeNewswire

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting

08 мар 2022 16:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in Two Upcoming Investor Conferences

28 фев 2022 06:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

24 фев 2022 15:03:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

17 фев 2022 06:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

10 фев 2022 06:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Expands Leadership Team with Key Promotions

01 фев 2022 15:01:00 Источник Nasdaq GlobeNewswire

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

20 янв 2022 15:01:00 Источник Nasdaq GlobeNewswire

Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

16 дек 2021 08:16:22 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

13 дек 2021 09:30:00 Источник Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax

13 дек 2021 06:00:01 Источник Nasdaq GlobeNewswire